Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives “Neutral” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report released on Monday morning, Benzinga reports. They currently have a $150.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on the stock. Citigroup upped their price target on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a buy rating in a research report on Tuesday, June 25th. Bank of America upped their price target on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a buy rating in a research report on Tuesday, June 25th. UBS Group upped their price target on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a buy rating in a research report on Friday. Canaccord Genuity Group reaffirmed a buy rating and set a $283.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, June 21st. Finally, Royal Bank of Canada upped their price target on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the stock an outperform rating in a research report on Tuesday, June 25th. Eight investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $246.41.

Alnylam Pharmaceuticals Stock Up 0.1 %

Shares of NASDAQ ALNY opened at $243.32 on Monday. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $252.87. The firm has a fifty day moving average of $161.82 and a 200-day moving average of $164.96. The stock has a market capitalization of $30.78 billion, a PE ratio of -90.79 and a beta of 0.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. During the same period in the prior year, the firm earned ($1.40) earnings per share. The firm’s quarterly revenue was up 54.8% on a year-over-year basis. Equities research analysts expect that Alnylam Pharmaceuticals will post -3.92 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now owns 136 shares in the company, valued at $30,013.84. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the sale, the chief executive officer now owns 80,534 shares in the company, valued at $18,602,548.66. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now owns 136 shares in the company, valued at approximately $30,013.84. The disclosure for this sale can be found here. Insiders have sold a total of 67,357 shares of company stock worth $13,436,711 over the last quarter. 1.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd grew its position in Alnylam Pharmaceuticals by 69.1% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock worth $36,203,000 after purchasing an additional 77,307 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after acquiring an additional 287,064 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 12,513 shares in the last quarter. Westpac Banking Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 59.8% in the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 566 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Alnylam Pharmaceuticals by 630.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock valued at $5,007,000 after acquiring an additional 22,580 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.